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A Randomized Comparison of
Triple-Site Versus Dual-Site Ventricular
Stimulation in Patients With Congestive Heart Failure
Christophe Leclercq, MD, PHD,* Fredrik Gadler, MD, PHD,† Wolfgang Kranig, MD,‡
Sue Ellery, MD,§ Daniel Gras, MD, Arnaud Lazarus, MD,¶ Jacques Clémenty, MD,#
Eric Boulogne, MSC,** Jean-Claude Daubert, MD,* for the TRIP-HF (Triple Resynchronization In
Paced Heart Failure Patients) Study Group
Rennes, Nantes, Paris, and Bordeaux, France; Stockholm, Sweden; Bad Rothenfelde, Germany;
Eastbourne, United Kingdom; and Zaventem, Belgium
Objectives We compared the effects of triple-site versus dual-site biventricular stimulation in candidates for cardiac resyn-
chronization therapy.
Background Conventional biventricular stimulation with a single right ventricular (RV) and a single left ventricular (LV) lead is
associated with persistence of cardiac dyssynchrony in up to 30% of patients.
Methods This multicenter, single-blind, crossover study enrolled 40 patients (mean age 70  9 years) with moderate-to-
severe heart failure despite optimal drug treatment, a mean LV ejection fraction of 26  11%, and permanent
atrial fibrillation requiring cardiac pacing for slow ventricular rate. A cardiac resynchronization therapy device
connected to 1 RV and 2 LV leads, inserted in 2 separate coronary sinus tributaries, was successfully implanted
in 34 patients. After 3 months of biventricular stimulation, the patients were randomly assigned to stimulation
for 3 months with either 1 RV and 2 LV leads (3-V) or to conventional stimulation with 1 RV and 1 LV lead (2-V),
then crossed over for 3 months to the alternate configuration. The primary study end point was quality of ventric-
ular resynchronization (Z ratio). Secondary end points included reverse LV remodeling, quality of life, distance
covered during 6-min hall walk, and procedure-related morbidity and mortality. Data from the 6- and 9-month
visits were combined to compare end points associated with 2-V versus 3-V.
Results Data eligible for protocol-defined analyses were available in 26 patients. No significant difference in Z ratio,
quality of life, and 6-min hall walk was observed between 2-V and 3-V. However, a significantly higher LV ejec-
tion fraction (27  11% vs. 35  11%; p  0.001) and smaller LV end-systolic volume (157  69 cm3 vs.
134  75 cm3; p  0.02) and diameter (57  12 mm vs. 54  10 mm; p  0.02) were observed with 3-V than
with 2-V. There was a single minor procedure-related complication.
Conclusions Cardiac resynchronization therapy with 1 RV and 2 LV leads was safe and associated with significantly more
LV reverse remodeling than conventional biventricular stimulation. (J Am Coll Cardiol 2008;51:1455–62)
© 2008 by the American College of Cardiology Foundation







nardiac resynchronization therapy (CRT) by simultaneous
r sequential biventricular stimulation alleviates symptoms,
mproves cardiac function, and prolongs survival in a high
ercentage of patients who present with drug-refractory
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ccepted November 28, 2007.hronic congestive heart failure (CHF), left ventricular (LV)
ystolic dysfunction, and a wide QRS complex (1–4).
revious studies have shown that CRT causes prominent
everse LV remodeling by decreasing the LV end-systolic
nd end-diastolic dimensions and by increasing left ventric-
See page 1463
lar ejection fraction (LVEF) (4,5–10). The prognostic
mportance of reverse LV remodeling in CRT was promi-
ently highlighted by Yu et al. (5), who found it to be a
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ever, significant LV reverse re-
modeling, defined as a 10%
decrease in left ventricular end-
systolic volume (LVESV), is
achieved in only 60% of pa-
tients with conventional biven-
tricular stimulation (5,6,9). This
inconsistent effect of CRT might
be due to incomplete resynchro-
nization (6), as intraventricular
and interventricular dyssynchrony
can persist in 25% to 30% of
patients during CRT (11). One
might hypothesize that stimulat-
ing the LV at a single site is
suboptimal and that stimulating
multiple LV sites might improve
ventricular resynchronization and,
consequently, further promote
reverse LV remodeling. A short-
term hemodynamic study has sug-
gested that stimulating 2 LV sites
simultaneously increased dP/dt,
pulse pressure, and LV end-
iastolic pressure significantly compared with pacing a single
V site (12).
The TRIP-HF (TRIPle Resynchronization in Paced
eart Failure Patients) trial was designed to examine
hether biventricular stimulation with 1 right ventricular
RV) and 2 LV leads increases the response to CRT and
roduces a greater improvement in cardiac performance and
V remodeling than standard biventricular stimulation in
atients with permanent atrial fibrillation (AF).
ethods
tudy design. This multicenter, single-blind, randomized
rossover study was designed to compare the safety and
fficacy of triple-site (3-V) versus dual-site (2-V) biventricu-
ar stimulation in patients who remained in New York
eart Association (NYHA) functional class III to IV
espite optimal medical therapy and presenting with per-
anent AF, and who had a slow ventricular rate requiring
ermanent cardiac pacing. The study protocol was reviewed
nd approved by the institutional ethics committee of each
articipating center, and the trial was conducted in compli-
nce with the Declaration of Helsinki.
After successful implantation, the device was pro-
rammed to pace in a conventional biventricular configura-
ion for 3 months after implant, to allow for stabilization of
he patient’s clinical status. After this run-in period, patients
ere randomly assigned to either 3 months of 3-V followed
y 3 months of 2-V stimulation (3-V ¡ 2-V group), or 3
Abbreviations
and Acronyms
AF  atrial fibrillation
AV  atrioventricular




CS  coronary sinus
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
NYHA  New York Heart
Association





6-MHW  6-min hall walkonths of 2-V followed by 3 months of 3-V stimulation 12-V ¡ 3-V group). After a 9-month follow-up, the trial
as completed, and the device programming was left to the
nvestigator’s choice.
tudy objective. The primary objective was to compare the
lobal quality of ventricular resynchronization by 2-V versus
-V stimulation by calculating the Z ratio, an echocardio-
raphic marker of abnormal ventricular activation (13). The
ain secondary end point was change in LVESV to assess
he degree of LV reverse remodeling with 2-V versus 3-V
timulation. Other secondary objectives of the study in-
luded: 1) changes in quality of life (QOL), as assessed by
he Minnesota Living With Heart Failure questionnaire,
nd exercise capacity, measured by the 6-min hall walk
6-MHW) test; and 2) procedure-related and overall mor-
idity and mortality.
atient selection and randomization. All study partici-
ants granted their informed consent. They were eligible for
nrollment if they fulfilled the following criteria: 1) NYHA
HF functional class III or IV despite optimal medical
herapy administered for 1 month; 2) permanent AF with
slow ventricular rate requiring permanent cardiac pacing
r planned to undergo atrioventricular (AV) node ablation;
nd 3) LVEF 35%. Exclusion criteria were: 1) indication
or an implantable cardioverter defibrillator; 2) myocardial
nfarction, cardiac surgery, or a coronary revascularization
rocedure within the previous 3 months; 3) chronic pulmo-
ary insufficiency or thyroid disease; 4) need for intravenous
notropic support for CHF; 5) 1-year life expectancy due
o a disorder other than CHF; or 6) inability to comply with
he follow-up procedures, 18 years of age, or pregnant.
Random assignment of the patients to one versus the
ther treatment sequence was performed and coordinated
entrally.
mplantation of the biventricular pacemaker system. A
rontier 5510 CRT pacemaker triple-chamber pulse gen-
rator (St. Jude Medical, Sylmar, California) was connected
o 1 RV and 2 LV leads. The techniques and instrumenta-
ion for implantation, including catheterization of the cor-
nary sinus (CS) and its tributaries, were those routinely
pplied at each study center. A first LV lead was inserted, if
ossible, into a postero-lateral or lateral vein. The second
V lead was placed as far as possible from the first lead, in
he anterior vein, a high antero-lateral vein, or the middle
ardiac vein. The RV lead was implanted according to each
enter’s usual practices. One LV and the RV lead were both
onnected to the ventricular ports, and the other LV lead
as connected to the atrial port of the pulse generator.
hus, in VVI mode, pacing was via the RV and LV1 leads,
n a standard biventricular (2-V) configuration, while in
DD mode, with a 25-ms (shortest programmable) AV
elay, pacing was via the 3 leads, in a triple-site (3-V)
onfiguration.
ata collection. The following information was collected,
nd measurements were made at the time of patient enroll-
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April 15, 2008:1455–62 Triple-Site Stimulation in CHFpeed; 2) echocardiogram for measurements of: a) LVEF; b)
ercent fractional shortening; c) aortic velocity time integral; d)
everity of mitral and tricuspid insufficiency, expressed as
egurgitation flow area in the 2- and 4-chamber views;
nd e) LV end-diastolic and end-systolic diameters and
olumes; 3) Minnesota Living with Heart Failure QOL
uestionnaire; and 4) 6-MHW test.
All echocardiographic measurements were performed by
core laboratory unaware of the treatment assignments
Appendix).
harmacologic treatment. Pharmacologic treatment was
ptimized before enrollment, and all efforts were made to
eep it stable for the duration of the study.
ratio calculation. The overall quality of ventricular
esynchronization was assessed by the Z ratio (13), mea-
ured from the duration of the ejection and filling times
ith respect to the overall cardiac cycle (Fig. 1): Z ratio 
LV ejection time  LV filling time)/RR interval.
When the study was designed, the Z ratio was considered
n accurate and reproducible (intraobserver coefficient of
ariation: 3.9%) (14) measure of abnormal ventricular acti-
ation and had been used already to evaluate the benefit of
RT (10).
The main study hypothesis was a significant increase in
he Z ratio by 3-V compared with 2-V pacing. During
ollow-up, the ejection and LV filling times used for the
alculation of the Z ratio were measured during pacing at
he programmed lower rate of 70 beats/min.
ample size calculation. A total of 27 patients were
eeded to detect a 10% difference in Z ratio in favor of 3-V
Figure 1 Calculation of the Z Ratio From Doppler Echocardiogr
ECG  electrocardiogram; Z ratio  (left ventricular ejection time  left ventriculaersus 2-V. Assuming a 1-sided, 5% significance level, 90%
ower, and 20% attrition rate, randomization of 34 patients
as calculated.
tatistical analyses. Data from the 6- and 9-month visits
ere combined to compare 2-V with 3-V by Student paired
test. The data were also examined for a possible carry-over
ffect using an unpaired t test. Normality of the data was
erified using box-and-whisker and normal probability
lots. The results were confirmed by nonparametric
tatistics, including Wilcoxon Mann-Whitney and Wil-
oxon signed rank tests. A p value 0.05 was considered
ignificant.
esults
low of the study and dropouts. Between March 2003
nd February 2005, 40 patients (38 men) were enrolled in
he trial, by 7 medical centers in 4 European countries
Appendix). The implant of 2 LV leads was unsuccessful in
patients, representing an 85% success rate. A standard
RT system was successfully implanted in 4 of these 6
atients, representing a 95% success of at least 1 LV lead
mplantation. The second LV lead could not be implanted
ecause of no other accessible vein in 2 patients, unstable
ead position in 1, and unacceptable pacing threshold in 1
atient. In the 2 remaining patients, no LV lead was
mplanted, because of CS dissection in 1 and inability to
annulate the CS ostium in the other. One patient, who had
ndergone successful implantation of the CRT system, died
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Triple-Site Stimulation in CHF April 15, 2008:1455–62atients were randomized. During follow-up, 1 patient died
f end-stage CHF; 2 patients withdrew their consent to
articipate; 1 patient developed a pulse generator pocket
nfection, which required explantation of the CRT system;
patient developed loss of capture at the LV1 lead; and,
ecause of cardiac decompensation, the system was repro-
rammed from triple- to double-site and from double- to
riple-site stimulation in 1 patient each. Ultimately, data
rom 26 patients were entered in the per-protocol statistical
nalyses. The flow of patients through the study is illus-
rated in Figure 2.
tudy population. The mean age of the 40 patients orig-
nally included in the study was 70  9 years and mean
VEF was 26  11%; 27 patients suffered from ischemic
eart disease and 35 patients were in NYHA functional
lass III. Additional baseline clinical characteristics of the
tudy population are listed in Table 1. Atrioventricular node
blation was performed because of uncontrollable ventricu-
ar rate in 14 patients (concomitant to the implant proce-
ure in 10 patients, before CRT implant in 4 patients), and
3 patients had a previously implanted single- or dual-
hamber pacemaker. The baseline echocardiographic obser-
ations made in the overall patient population, in 34
atients who received CRT systems, and in 26 patients
ligible for inclusion in the per-protocol analysis are shown
n Table 2.
rocedural observations. In the 34 patients who under-
ent successful implantation procedures, the 2 LV leads
ere placed in a lateral or postero-lateral position in 33
ases, in an antero-lateral position in 14, in an anterior
osition in 15, in the middle cardiac vein in 4, and in an
nfero-lateral position in 2 cases. The RV lead was placed in
Figure 2 Enrollment, Randomization, and Outcomes of Enrolled
2V  dual-site; 3V  triple-site.septal position in 23 patients (68%), at the apex in 8
atients (24%), and at other locations in 3 patients (8%). A
epresentative example of the position of the 3 leads is
hown in Figure 3. The mean duration of the implant
rocedure and fluoroscopic exposure was 2.03  0.97 h and
6.3  24.6 min, respectively.
ollow-up observations. After 3 months of standard biven-
ricular stimulation, the distance covered during the 6-MHW
est increased by a mean of 44 m (p  0.0019), QOL score
ecreased by 15 points (p  0.0001), LVEF increased by 7%
p  0.026), and LVESV decreased by a mean of 20 ml (p 
.048). No significant change was observed in the Z ratio.
-V VERSUS 2-V STIMULATION. No statistically significant
ifference in Z ratio was observed between 2-V (0.78 
.09) and 3-V stimulation (0.76  0.12) (p  0.9423)
Fig. 4). In contrast, other 2-V versus 3-V comparisons
evealed a statistically significant increase in LVEF, from
7  11% to 35  13% (p  0.0010) (Fig. 5), a decrease in
VESV from 157.4  69.0 cm3 to 134.4  75.2 cm3 (p 
.0191) (Fig. 6), and a decrease in LV end-systolic diameter
rom 57.0  11.9 mm to 53.9  10.2 mm (p  0.0242), all
avoring 3-V stimulation (Table 3). The proportion of
atients in whom LVESV decreased 10% from baseline
ncreased from 67% with 2-V stimulation to 78% with 3-V
timulation (p  0.1573).
In patients in whom LVESV decreased 10%, 3-V
acing further decreased nonsignificantly LVESV from
63  88 ml to 138  75 ml. In patients in whom LVESV
id not decrease initially, 4 became responders under 3-V
acing and led to a nonsignificant decrease in LVESV from
47  57 ml to 125  86 ml.
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April 15, 2008:1455–62 Triple-Site Stimulation in CHFThe distance covered during the 6-MHW test was
30.6  101.5 m in 2-V and 401.6  91.3 m in 3-V (p 
.0578), and the QOL score was 21.6  18.3 in 2-V
ompared with 22.1  18.9 in 3-V (p  0.7541).
The mean QRS width increased from 154.7 24.8 ms in
-V to 171.4  20.1 ms in 3-V (p  0.0112).
dverse events. The only procedure-related adverse event
as an uncomplicated dissection of the CS. During follow-
p, 2 patients (5%) died from end-stage CHF. Other
dverse events that occurred during long-term follow-up in
he overall patient population are listed in Table 4. These
dverse events either prolonged or prompted a hospitaliza-
ion in 17 instances. One patient hospitalized for cardiac
ecompensation was prematurely reprogrammed from 2-V
o 3-V, and another patient complaining from dyspnea at
est was prematurely reprogrammed from 3-V to 2-V.
Baseline Characteristics of the Overall Patient P
Table 1 Baseline Characteristics of the Ove
Age, yrs
Men/women (% of patients)
Ischemic/nonischemic heart disease (% of patients)
NYHA functional class III/IV (% of patients)
ACE inhibitor/ARB therapy (% of patients)
Beta-adrenergic blocker therapy (% of patients)
Prior atrioventricular node ablation (number of patients)
Previously implanted system (number of patients)
6-min hall walk test, m







Unless specified otherwise, values are means  standard deviation.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor
aseline Echocardiographic Observationsade in Baseline, Implant, and Analyzed Patients








End-systolic volume, ml 147 75 154 76 154 68
End-diastolic volume, ml 192 85 197 80 197 68
Ejection fraction, % 26 11 24 11 24 11
End-diastolic diameter, mm 65 8 66 8 66 7
End-systolic diameter, mm 56 8 57 8 57 8
Ejection time, ms 239 38 237 39 238 36
Filling time, ms 355 116 348 122 344 133
Aortic velocity time integral, cm/s 16.7 9.6 16.7 10.1 16.1 8.3
Z ratio 0.74 0.11 0.74 0.12 0.75 0.12
alues are means  standard deviation.
Analyzed  patients entered into the per-protocol analysis; Baseline  the overall patient
opulation; Implant  patients who underwent successful cardiac resynchronization therapy
ystem implantations.iscussion
his was the first prospective, randomized study to dem-
nstrate that the degree of LV reverse remodeling was
ignificantly greater when long-term CRT was delivered by
eans of 1 RV and 2 LV leads than when delivered by
eans of 1 RV and a single LV lead in patients presenting
ith advanced CHF, permanent AF, and indications for
ermanent pacing.
Published studies of the effects of CRT in patients
uffering from AF are few (15–19). The MUSTIC (Multi-
ite Stimulation in Cardiomyopathies) AF study, which
ompared the effects of single-site RV versus biventricular
timulation in patients with advanced CHF, depressed LV
unction, and a wide RV-paced QRS complex showed a
Representative Frontal Roentgenographic View of the
ation and of Each Study Group















322 125 337 118 352 113
44 19 42 19 40 20
163 43 162 43 159 47
65 8 66 8 66 7
147 75 154 76 154 68
192 85 197 81 197 68
26 11 24 11 24 11
r; NYHA  New York Heart Association.Figure 3opul
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Triple-Site Stimulation in CHF April 15, 2008:1455–62ignificant increase in exercise capacity with biventricular
timulation (15). The PAVE (Biventricular Pacing After
blate Compared With Right Ventricular Therapy) trial,
hich included candidates for AV node ablation, regardless
f LVEF and QRS duration, and excluded patients in
YHA functional class IV, observed an increase in the
istance covered during a 6-MHW and in LVEF by
iventricular stimulation, particularly in patients with an
VEF 45% and poorly tolerated AF (16). The OPSITE
Optimal Pacing SITE) trial compared the effects of RV,
V, and biventricular pacing in a heterogeneous population
f patients presenting with permanent AF and indication
or AV node ablation for severely symptomatic, uncon-
rolled ventricular rate and depressed LV function or left
undle branch block, or both (17). Compared with RV
Figure 4 Evolution of Mean Z Ratio Between Patient
Enrollment and End of Follow-Up in Each Study Group
In both groups, after the stabilization phase, the Z ratio increased during the
period of triple-site biventricular stimulation, and decreased during dual-site
stimulation. Abbreviations as in Figure 2.
Figure 5 Evolution of Mean LVEF Between Patient
Enrollment and End of Follow-Up in Each Study Group
In both groups, after the stabilization phase, left ventricular ejection fraction
(LVEF) increased during the period of triple-site biventricular stimulation and
decreased during dual-site stimulation. Abbreviations as in Figure 2.2acing, biventricular pacing significantly improved QOL,
ecreased NYHA functional class, and increased LVEF.
asparini et al. (18) observed that the benefits conferred by
RT in candidates for CRT presenting with AF were
imited to patients who had previously undergone ablation
f the AV node. In 74 patients with permanent AF and a
low ventricular rate, Kiès et al. (19) found that CRT caused
significant decrease in LV end-systolic, LV end-diastolic,
nd left atrial diameter, and a significant increase in LVEF.
he significant improvement in QOL, increase in distance
overed during the 6-MHW test and in LVEF, and
ecrease in LVESV observed after 3 months of standard
iventricular stimulation in our study are consistent with the
esults of these previous studies.
The effects of long-term CRT delivered by means of 2
V and 1 RV lead have not been studied systematically.
assara et al. (20) described a patient presenting with
ermanent AF and a VVI pacemaker implanted for slow
entricular rate who underwent CRT with 2 leads im-
lanted on the postero-basal and antero-lateral epicardial
V surface, respectively, and an RV lead implanted trans-
enously. At 3 months of follow-up, a clinical improvement
s well as a significant reduction in LV volumes was
bserved with 3-V pacing. It is noteworthy that the
Figure 6 Evolution of Mean LVESV Between Patient
Enrollment and End of Follow-Up in Each Study Group
LVESV left ventricular end-systolic
volume; other abbreviations as in Figure 2.
ombined Echocardiographic Measurements Madet 6 a d 9 Months After 3 Months of 2-V VersusMonths of 3-V Biventricular S imulation
Table 3
Combined Echocardiographic Measurements Made
at 6 and 9 Months After 3 Months of 2-V Versus
3 Months of 3-V Biventricular Stimulation
Variable 2-V 3-V p Value
Left ventricular
End-diastolic volume, cm3 213.2 83.6 198.5 95.7 0.2639
End-systolic volume, cm3 157.4 69.0 134.4 75.2 0.0191
Ejection fraction, % 27 11 35 13 0.0010
End-diastolic diameter, mm 66.4 8.2 65.1 8.5 0.1773
End-systolic diameter, mm 57.0 11.9 53.9 10.2 0.0242
Aortic velocity time integral, cm 16.0 7.3 15.1 6.0 0.9527
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April 15, 2008:1455–62 Triple-Site Stimulation in CHFhortening of the inter- and intraventricular delays was
reater with 3-V than with 2-V or “conventional” biven-
ricular pacing.
The immediate hemodynamic effects of stimulating a
ingle versus 2 LV sites in 14 patients with low LVEF and
ide QRS, in NYHA functional class III or IV and in sinus
hythm, have been reported by Pappone et al. (12). Dual
V stimulation caused significantly greater increases in
eak dP/dt and pulse pressure than posterior base or
ateral wall pacing.
The TRIP-HF trial showed that, compared with dual-
ite biventricular stimulation, triple-site biventricular stim-
lation further promoted LV reverse remodeling, and fur-
her decreased LVESV and increases LVEF. A post hoc
nalysis of response to CRT, defined by a10% decrease in
VESV, showed that: 1) in responders to 2-V stimulation,
-V stimulation further improved the magnitude of remod-
ling; and 2) among the 10 patients who did not respond to
months of 2-V, 4 patients became responders to 3-V. The
ndependent prognostic importance of LV remodeling has
een confirmed by several studies (21–24). Morbidity and
ortality increased, irrespective of CHF etiology, in pro-
ortion to LV enlargement and deterioration of contractile
erformance. In a substudy of the Val-HeFT (Valsartan
eart Failure Trial) study, LV end-diastolic diameter and
VEF measured echocardiographically were powerful pre-
ictors of morbidity and mortality, irrespective of treatment
23). Similar observations were made recently by Yu et al.
5) in a nonrandomized study of 141 recipients of CRT
ystems. A 10% decrease in LVESV after CRT system
mplantation was strongly predictive of a lower long-term
ortality and CHF-related events. This recent report em-
hasized the increasing relevance of the remodeling process
s a biomarker in CHF studies, and slowing or reversing
emodeling has become a goal of CHF treatment (25).
hile therapeutic objectives used to be mostly concentrated
n the relief of symptoms, attention is now focused on the
lowing or halting of disease progression. Furthermore, the
dverse Clinical Events in 40 Patientsho Underwent Implantation of CRT Systems
Table 4 Adverse Clinical Events in 40 PatientsWho Underwent Implantation of CRT Systems
Event Number (%) of Patients
Procedure-related
Coronary sinus perforation 1 (2.5)
Long-term
Severe dyspnea 10 (25)
Diaphragmatic stimulation* 5 (12.5)
Prominent edema 3 (7.5)
Death from end-stage heart failure 2 (5)
Explantation of infected system† 2 (5)
Device hardware reset 1 (2.5)
1 adverse event may have occurred in the same patient. *A dislodged lead was repositioned in
of these patients; †the system was reimplanted in 1 patient who completed the study.
CRT  cardiac resynchronization therapy.lowing or reversal of cardiac remodeling appears closely uelated to the relief of symptoms and improvement in
rognosis.
The absence of difference in Z ratio between the 2 pacing
odes might have at least 2 explanations. First, since the
atients were not selected on the basis of the QRS duration,
0% had a QRS duration 150 ms. Therefore, the baseline
ratio was 0.75  12, considerably higher than that
bserved in the MUSTIC SR trial, where all patients had a
RS duration150 ms (10). Second, since 3-V stimulation
as delivered with 1 LV lead connected to the atrial port
nd 2 leads to the ventricular ports, with a minimal AV
elay of 25 ms in DDDR mode, the QRS during 3-V
acing was longer by a mean value of 25 ms than during
conventional” biventricular stimulation.
The absence of further improvement in QOL and in-
rease in distance covered during the 6-MHW test by 3-V
timulation compared with conventional CRT was perhaps
ue to the prior therapeutic effects conferred by the
-month run-in period of biventricular stimulation.
echnical considerations. When this study began, in
003, all of the new instrumentation designed to facilitate
he access to the coronary veins and increase the implanta-
ion success rate was not available. Despite this constraint,
n acceptable 85% success rate of implantation of 2 LV leads
as reached,1 lead was implanted in 95% of patients, and
ailure to implant any LV lead was limited to 2 patients.
hese procedural results are similar to those achieved in the
ain randomized studies of CRT. The overall duration of
he implant procedures and fluoroscopic exposure was
onger than for standard CRT system implantations and
ould probably be shorter with the new delivery tools that
re currently available. The absence of major procedure-
elated adverse cardiac events and the relatively low rate of
ong-term device-related complications, despite the com-
lexity of the technique, are noteworthy.
tudy limitations. This study was conducted in patients
resenting with permanent AF in order to examine the sole
ffect of changing the ventricular activation sequence by chang-
ng the ventricular pacing site(s), while avoiding any interfer-
nce with atrial function and AV synchrony. Another goal was
o obviate the need for Y connectors, which are notorious for
ncreasing the rate of long-term complications. As mentioned
reviously, a 25-ms delay between 1 LV and the other 2
entricular leads might have lowered the quality of ventricular
esynchronization. The absence of precise assessment of ven-
ricular dyssynchrony with techniques that were not widely
vailable when this study was conducted, such as tissue Dopp-
er imaging, is another limitation. Finally, these results, col-
ected in a small number of patients during a short follow-up
eriod (3 months), should be confirmed in a larger population
ver a longer period.
onclusions
riple-site biventricular stimulation, with simultaneous stim-
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Triple-Site Stimulation in CHF April 15, 2008:1455–62VEF and LVESV than standard 2-V biventricular stim-
lation. At 3 months of follow-up, 3-V biventricular and
onventional biventricular stimulation had similar effects on
OL and 6-MHW. Triple-site biventricular stimulation
as achievable with an acceptable rate of complications.
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